Cypress Motor Sports. 2026

 

Cypress Motor Sports. 2026

Operating separate from S.B.G - CIG under the 22nd Firm CITY as an In-House Brand with The Shield Network for Retail & Maintenance 

Delivery & Our slow marketing + branding integration effect. 2026-2027 

MASS SCALE SCALE-UP CAPABILITIES 

We have a smaller than larger percentage of mold & Point A - B on parts & full builds assembly now separate from custom-fab efforts from digital to re-use molds in preparation for mass scale production (In-House + external)

Material storage + 2 point assembly (Block 11)

EXFERNAL SUPPLY & IN-HOUSE 

EESM Motors & specifics digital more so integration have barriers to delivery per quarter 

We have a set standard then higher output & higher torque models altered for different platforms 

MARKETING & ADVERTISING MATERIALS 

Shield Network Stores & Partner Stores

We are prepping a second + third+ round of shipments with digital - physical materials 

Our video content commercials are pre-determined yet licencing on music & specifics is incomplete for some not all 

Rechargers. Out vast prototype options Vs production variations 

https://jobopsatsbg.blogspot.com/2026/01/cm-recharger-thought.html

For 2026. Unlimited Range grows internationally in Ground Up & Retrofit Kitting

We have to licence the Chello Basttard & others still & get some H.I.3 & connected projects moving out of a shelfed effect 

https://youtu.be/0C-dNgypA5M?si=rhNqxqyylJsC8hND

TRANSMISSION SELECTION - AUTOMOTIVE 

Standard issue. 

Automotive standard yet (optional)

Sequential without clutch or non manual with simulated yet working clutch 

An integrated roll back system is in effect regardless 

(Many C/M models come equipped with the 3)

Regular. Sport & relaxed modes 

Digital - Energy & Switch-Back monitoring on components 

This allows for performance mapping & additive traction control effects for variable conditions & performance 

"Anyone that can obtain a licence in an automatic can drive 90-98% of C/M vehicles in amy form including Commercial or Off-Road or Industrial" 

Every build shares similarities & differences are equipped with Mandatory & Standard Issue efforts separate from Optional 

 

The 22nd Firm CITY has connected Investments & Commodities efforts with S.B.G - CIG as a foundational background effect in managed efforts & operates using CIG Infrastructure to source material 

CYPRESS MOTOR SPORTS

Privatized - Punlicly Traded hybrid scale up 2026-2027

https://jobopsatsbg.blogspot.com/2025/12/cm-cypress-motor-sports.html

Trillions Investments Group backing. 100+ year guarantee staying power. Relevance 

Like a Hollywood broads 25+ year effort 

Dolled & all the snealy backend non-sense she never did

PRIORITY IS BUILDING 

Parts & units then catalogues + manuals with then digitalizing for 3 Part Website access & separate Shield Network 

Tedious & repeatative with design teams 

Q1-4 2026 whike everything co.es together after delays due to H.I.3 NB-OT Labs & expansion Labs 

Scientists Unveil Breakthrough Method to Mass-Produce Cancer-Fighting Natural Killer Cells

A new method for engineering natural killer cells could make cancer immunotherapy more efficient, scalable, and affordable, potentially reshaping how these treatments are produced.

Chinese scientists have reported a new technique that makes it easier to genetically modify natural killer (NK) cells for use in cancer immunotherapy.

In the immune system, NK cells provide rapid, early protection against viruses and cancer, along with other important functions. That combination has made them a strong candidate for immunotherapy. One example is chimeric antigen receptor (CAR)-NK therapy, where researchers equip an NK cell with a lab-built receptor (a CAR) so it can spot a specific antigen on a cancer cell and then attack.

Many current CAR-NK approaches depend on mature NK cells taken from human sources such as peripheral blood or cord blood. This strategy can be difficult to scale because the cells vary widely from donor to donor, are harder to engineer efficiently, require costly handling, and often involve lengthy processing.

A New Strategy Using Stem and Progenitor Cells

A team led by Prof. Jinyong Wang from the Institute of Zoology of the Chinese Academy of Sciences has now introduced a method for producing induced (that is, lab-generated) NK (iNK) cells and CAR-engineered iNK (CAR-iNK) cells using CD34+ hematopoietic stem and progenitor cells (HSPCs) collected from cord blood.

The study was recently published in Nature Biomedical Engineering.
Past attempts to generate NK cells from cord blood-derived CD34+ HSPCs have been hindered by poor induction efficiency and the resulting cells’ functional immaturity. To overcome these barriers, the researchers shifted the genetic engineering to the earlier CD34+ HSPC stage, combining CAR transduction, efficient progenitor expansion, and NK-lineage commitment.

A Three-Step Engineering Process

The three-step process began with expanding CD34+ HSPCs (or CD19 CAR-transduced HSPCs) using irradiated AFT024 feeder cells, achieving approximately 800- to 1,000-fold growth within 14 days. Next, the expanded cells were co-cultured with OP9 feeder cells to form artificial hematopoietic organoid aggregates—structures that promote efficient NK lineage commitment and development. Finally, the cells committed to the NK lineage underwent maturation and proliferation, yielding highly pure iNK or CAR-iNK cells that expressed endogenous CD16.

Notably, the method demonstrated that a single CD34+ HSPC could produce up to 14 million iNK cells or 7.6 million CAR-iNK cells. In theory, just one-fifth of a standard cord blood unit could generate enough cells to supply thousands—or even tens of thousands—of therapeutic doses.

A major advance is the drastic reduction in the amount of viral vector required for CAR engineering. Compared with the viral load typically needed to engineer mature NK cells, the new method used only ~1/140,000 (by Day 42 of culture) to ~1/600,000 (by Day 49) as much vector.

Functional Validation in Cancer Models

In functional tests, the team confirmed that both iNK and CAR-iNK cells exhibited strong tumor-killing activity. In cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models of human B-cell acute lymphoblastic leukemia (B-ALL), CD19 CAR-iNK cells suppressed tumor growth and prolonged the survival of the animals.

The new method not only boosted the induction efficiency of iNK and CAR-iNK cells but also substantially lowered the cost of CAR engineering, the researchers noted.

Reference: “Large-scale generation of iNK and CAR-iNK cells from CD34+ haematopoietic stem and progenitor cells for adoptive immunotherapy” by Fangxiao Hu, Jianhuan Li, Yao Wang, Yunqing Lin, Jingliao Zhang, Jiacheng Xu, Xiujuan Zheng, Qitong Weng, Xiaofei Liu, Yang Geng, Hongling Wu, Lijuan Liu, Huan Peng, Bingyan Wu, Dehao Huang, Chengxiang Xia, Tongjie Wang, Xin Du, Hui Zeng, Fang Dong, Yingchi Zhang, Xiaofan Zhu, Mengyun Zhang and Jinyong Wang, 7 October 2025, Nature Biomedical Engineering.

DOI: 10.1038/s41551-025-01522-5
Funding for the research was provided by the Ministry of Science and Technology of the People’s Republic of China and the National Natural Science Foundation of China, among others.

A team led by Prof. Jinyong Wang from the Institute of Zoology of the Chinese Academy of Sciences has now introduced a method for producing induced (that is, lab-generated) NK (iNK) cells and CAR-engineered iNK (CAR-iNK) cells using CD34+ hematopoietic stem and progenitor cells (HSPCs) collected from cord blood.

https://scitechdaily.com/scientists-unveil-breakthrough-method-to-mass-produce-cancer-fighting-natural-killer-cells/

Innovation. Magnet recycling 

https://interestingengineering.com/innovation/dead-magnets-turned-into-high-purity

S.B.G - CIG